http://www.docguide.com/vorapaxar-secondary-stroke-prevention-perspectives-and-obstacles?
Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 29,372 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Monday, November 30, 2015
Vorapaxar for secondary stroke prevention: perspectives and obstacles
Have not heard of this before so this is strictly up to your doctor and hospital to decide on. Once they know about it after YOU tell them to investigate this. Pay it forward, we have to do the work that our stroke associations are completely failing at.
http://www.docguide.com/vorapaxar-secondary-stroke-prevention-perspectives-and-obstacles?
Vorapaxar,
a novel antiplatelet thrombin protease-activated receptor 1 (PAR-1)
inhibitor, has been evaluated in the successful TRA2P trial and failed
TRACER trial. The drug is currently approved for post myocardial
infarction and peripheral artery disease indications on top of
clopidogrel and/or aspirin. The stroke data after vorapaxar are mixed,
dominated with heavy excess of intracranial bleeding risks and slightly
worsened second stroke rates, but show less primary ischemic strokes.
Fortunately, these conflicting data do not belong purely to vorapaxar
per se but rather, reflect unreasonably aggressive strategies, including
predominantly triple antiplatelet therapy, utilized in both Trial to
Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke
in Patients with Arteriosclerosis (TRA2P) and especially in
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
(TRACER). The FDA-confirmed evidence strongly suggests that unique
pharmacokinetics and a very mild'comfort zone'antiplatelet profile makes
vorapaxar a good candidate for improved secondary stroke prevention.
The outcome-driven, randomized trial should test head-to-head
monotherapy with vorapaxar (Zontivity®) versus clopidogrel (Plavix®) and
versus dipyridamole with very low dose aspirin (Aggrenox®). The
advantages and potential pitfalls of such a trial are discussed in this
article.
http://www.docguide.com/vorapaxar-secondary-stroke-prevention-perspectives-and-obstacles?
No comments:
Post a Comment